Carotid Endarterectomy Versus Carotid Artery Stenting in Asymptomatic Patients (ACST-2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00883402 |
Recruitment Status : Unknown
Verified April 2019 by University of Oxford.
Recruitment status was: Recruiting
First Posted : April 17, 2009
Last Update Posted : March 24, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The trial randomise patients with asymptomatic carotid artery narrowing in whom prompt physical intervention is thought to be needed, but there there is still substantial uncertainty shared by patient and doctor about whether surgery or stenting is the more appropriate choice.
The study is looking at immediate risks (within one month)and at long term benefits
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Carotid Stenosis | Procedure: CEA, CAS | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 3600 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Asymptomatic Carotid Surgery Trial-2 (ACST-2): an International Randomised Trial to Compare Carotid Endarterectomy With Carotid Artery Stenting to Prevent Stroke |
Study Start Date : | January 2008 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | December 2020 |
Arm | Intervention/treatment |
---|---|
Active Comparator: CEA
Carotid endarterectomy
|
Procedure: CEA, CAS
Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA) |
Active Comparator: CAS
Carotid Artery Stenting
|
Procedure: CEA, CAS
Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA) |
- To compare peri-procedural risks (MI, stroke and death) within the first month after the allocated CEA or CAS and long-term (up to 5 or more years) prevention of stroke, particularly disabling or fatal stroke, in subsequent years. [ Time Frame: 10 years ]
- To identify types of patients to be identified in which one or other procedure is clearly preferable as well as economic evaluation; procedural costs and stroke-related healthcare costs and quality of life. [ Time Frame: 10 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Carotid artery stenosis detectable by duplex ultrasound, with no ipsilateral carotid territory symptoms(or none for some months) and no previous procedure done on it, which might well need procedural treatment now with CEA or CAS.
- Already started any appropriate medical treatment (eg, statin, aspirin etc), and already recovered from any necessary coronary procedures (eg, CABG)
- Patient seems fit and willing for follow-up in person (at 1 month) and by annual letter (for at least 5 years)
- Investigations show that both procedures (CEA and CAS) appear to be practicable and appropriate
- Some type of angiography (eg, MRA or CTA) has already been done that has shown that CEA and CAS would both be anatomically practicable.
- Doctor and patient both substantially uncertain about whether to treat with CEA or CAS, and the doctor sees no clear indication/contra-indication for either procedure
Exclusion Criteria:
- Small likelihood of worthwhile benefit (eg, very low risk of stroke because stenosis is very minor, or major co-morbidity or life-threatening disease, such as advanced cancer)
- Unsuitable for one or other procedure (eg, stenosis at carotid siphon that is inaccessible for CEA, or complex vasculature below the stenosis that would hinder CAS, or patient unfit for major surgery)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00883402
Contact: Alison Halliday | + 44 1865 617975 | acst@nds.ox.ac.uk | |
Contact: Richard Bulbulia | +44 1865 743891 | acst@nds.ox.ac.uk |

Principal Investigator: | Alison Halliday | University of Oxford |
Publications:
Responsible Party: | University of Oxford |
ClinicalTrials.gov Identifier: | NCT00883402 |
Other Study ID Numbers: |
ACST-2 |
First Posted: | April 17, 2009 Key Record Dates |
Last Update Posted: | March 24, 2020 |
Last Verified: | April 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carotid stenosis CEA CAS Stenting |
Carotid Stenosis Carotid Artery Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases |